Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.
Georgia
elimination
hepatitis C
prevalence
serosurvey
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
18
11
2022
accepted:
15
03
2023
pmc-release:
15
09
2024
medline:
18
9
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
The country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and 5.4%, respectively. This analysis reports hepatitis C results of a follow-up serosurvey conducted in 2021, and progress towards elimination. The serosurvey used a stratified, multistage cluster design with systematic sampling to include adults and children (aged 5-17 years) providing consent (or assent with parental consent). Blood samples were tested for anti-HCV and if positive, HCV RNA. Weighted proportions and 95% confidence intervals (CI) were compared with 2015 age-adjusted estimates. Overall, 7237 adults and 1473 children were surveyed. Among adults, the prevalence of anti-HCV was 6.8% (95% CI, 5.9-7.7). The HCV RNA prevalence was 1.8% (95% CI, 1.3-2.4), representing a 67% reduction since 2015. HCV RNA prevalence decreased among those reporting risk factors of ever injecting drugs (51.1% to 17.8%), and ever receiving a blood transfusion (13.1% to 3.8%; both P < .001). No children tested positive for anti-HCV or HCV RNA. These results demonstrate substantial progress made in Georgia since 2015. These findings can inform strategies to meet HCV elimination targets.
Sections du résumé
BACKGROUND
The country of Georgia initiated its hepatitis C virus (HCV) elimination program in 2015, at which point a serosurvey showed the adult prevalence of HCV antibody (anti-HCV) and HCV RNA to be 7.7% and 5.4%, respectively. This analysis reports hepatitis C results of a follow-up serosurvey conducted in 2021, and progress towards elimination.
METHODS
The serosurvey used a stratified, multistage cluster design with systematic sampling to include adults and children (aged 5-17 years) providing consent (or assent with parental consent). Blood samples were tested for anti-HCV and if positive, HCV RNA. Weighted proportions and 95% confidence intervals (CI) were compared with 2015 age-adjusted estimates.
RESULTS
Overall, 7237 adults and 1473 children were surveyed. Among adults, the prevalence of anti-HCV was 6.8% (95% CI, 5.9-7.7). The HCV RNA prevalence was 1.8% (95% CI, 1.3-2.4), representing a 67% reduction since 2015. HCV RNA prevalence decreased among those reporting risk factors of ever injecting drugs (51.1% to 17.8%), and ever receiving a blood transfusion (13.1% to 3.8%; both P < .001). No children tested positive for anti-HCV or HCV RNA.
CONCLUSIONS
These results demonstrate substantial progress made in Georgia since 2015. These findings can inform strategies to meet HCV elimination targets.
Identifiants
pubmed: 36932731
pii: 7080306
doi: 10.1093/infdis/jiad064
pmc: PMC10506179
mid: NIHMS1902464
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-693Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : CDC HHS
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.
Déclaration de conflit d'intérêts
Potential conflicts of interest. F. A. and G. C. are employed by and own stock in Abbott Diagnostics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
PLoS One. 2019 Apr 9;14(4):e0214785
pubmed: 30964906
J Hepatol. 2020 Apr;72(4):680-687
pubmed: 31811882
Prev Med. 2020 Sep;138:106153
pubmed: 32473265
BMC Public Health. 2019 May 10;19(Suppl 3):466
pubmed: 32326938
Transfusion. 2020 Jun;60(6):1243-1252
pubmed: 32542715
Public Health. 2022 Apr;205:182-186
pubmed: 35305459
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7
pubmed: 26203628
Hepatology. 2021 Nov;74(5):2366-2379
pubmed: 34105797
Clin Infect Dis. 2020 Aug 22;71(5):1263-1268
pubmed: 31563938
BMC Public Health. 2019 May 10;19(Suppl 3):480
pubmed: 32326913
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56
pubmed: 33217341
BMJ Open. 2019 Sep 24;9(9):e029538
pubmed: 31551376
MMWR Morb Mortal Wkly Rep. 2019 Jul 26;68(29):637-641
pubmed: 31344021